SA-4503,1-(3,4-DIMETHOXYPHENETHYL)-4-(3-PHENYLPROPYL)PIPERAZINE DIHYDROCHLORIDE

SA-4503,1-(3,4-DIMETHOXYPHENETHYL)-4-(3-PHENYLPROPYL)PIPERAZINE DIHYDROCHLORIDE Property

Melting point:

250-252°C

storage temp. 

2-8°C

solubility 

Soluble in DMSO (up to 5 mg/ml) or in Water (up to at least 25 mg/ml)..

form 

powder

color 

white to beige

Water Solubility 

H2O: 2mg/mL, clear

Stability:

Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month.

Hazard and Precautionary Statements (GHS)

SA-4503,1-(3,4-DIMETHOXYPHENETHYL)-4-(3-PHENYLPROPYL)PIPERAZINE DIHYDROCHLORIDE Chemical Properties,Usage,Production

Description

SA4503 (165377-44-6) is a potent and selective sigma 1 agonist (σ1 IC50?= 17.4 nM, σ2 IC50?= 1784 nM).1?It has been investigated as a cognition enhancer2,3, antidepressant4,5, anti-addiction agent6, and neuroprotectant7-10.

Uses

SA 4503 Dihydrochloride is a novel and selective σ1 receptor agonist.

Biochem/physiol Actions

SA4503 is a high affinity, orally active non-opioid intracellular receptor sigma-1 (σ1R) selective agonist (IC50 = 17.4 nM against 200 nM (+)-pentazocine for binding σ1R), exhibiting ~100-fold less affinity for the sigma 2 receptor subtype (σ2R) and little or no affinity toward 36 other receptors, ion channels and second messenger systems. Oral administration is reported to elicit cerebral acetylcholine (ACh) release in rat frontal cortex and hippocampus (5-20 mg/kg p.o.) and reduce immobility time in a mouse forced swimming test (Immobility time = 214.8 s without vs. 111.6 s with 1.0 mg/kg oral dosage).

in vivo

IC 50

Sigma 1 Receptor

storage

Desiccate at RT

References

[1] KIYOSHI MATSUNO. Binding properties of SA4503, a novel and selective σ1 receptor agonist[J]. European journal of pharmacology, 1996, 306 1: Pages 271-279. DOI:10.1016/0014-2999(96)00201-4
[2] SA4503, a novel cognition enhancer with sigma 1 agonistic properties
[3] TOMIHISA NIITSU K H Masaomi Iyo. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases.[J]. Current pharmaceutical design, 2012, 18 7: 875-883. DOI:10.2174/138161212799436476
[4] G SKUZA  Z R. A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist.[J]. Behavioural Pharmacology, 2002, 13 7: 537-543. DOI:10.1097/00008877-200211000-00003
[5] GUILLAUME LUCAS. Further evidence for an antidepressant potential of the selective sigma1 agonist SA 4503: electrophysiological, morphological and behavioural studies.[J]. International Journal of Neuropsychopharmacology, 2008, 11 4: 485-495. DOI:10.1017/s1461145708008547
[6] TOMOHISA MORI. Inhibitory effects of SA4503 on the rewarding effects of abused drugs.[J]. Addiction Biology, 2014, 19 3: 362-369. DOI:10.1111/j.1369-1600.2012.00488.x
[7] MINAKO NAKAZAWA  Shiro M  Kiyoshi Matsuno. Activation of σ1 receptor subtype leads to neuroprotection in the rat primary neuronal cultures[J]. Neurochemistry international, 1998, 32 4: Pages 337-343. DOI:10.1016/s0197-0186(97)00105-8
[8] KARSTEN RUSCHER. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke.[J]. ACS Central Science, 2011: 732-746. DOI:10.1093/brain/awq367
[9] KARSTEN RUSCHER. Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke.[J]. ACS Applied Bio Materials, 2012: e45118. DOI:10.1371/journal.pone.0045118
[10] DAISUKE YAMASHITA. Neuroprotective effects of cutamesine, a ligand of the sigma-1 receptor chaperone, against noise-induced hearing loss[J]. Journal of Neuroscience Research, 2015, 93 5: 788-795. DOI:10.1002/jnr.23543